Agarose Bead Technologies (ABT), a manufacturer of high-quality agarose resins with locations in the U.S. and Europe, has plans for further expansion, strengthening its international presence, enhancing its tailor-made chromatography solutions, and investing in process scalability.

ABT’s agarose resins are widely applied in the purification of monoclonal antibodies (mAbs), advanced cell and gene therapies (ATMPs), lipid nanoparticles (LNPs) for mRNA delivery, recombinant proteins, and therapeutic oligonucleotides.

Following the $5 million investment in the expansion of its Burgos facility last year, ABT is expanding its global presence in new international markets, including India and the U.S. It also plans to extend its expertise in tailor-made solutions by offering a design and manufacture of customized resins service for biopharmaceutical companies. 

ABT will also invest in the scalability of its technologies and processes to support customers and enhance its logistics and storage infrastructure to secure an uninterrupted global supply of products. 

Carolina Egea, General Manager, Agarose Bead Technologies, said, “As we celebrate our 25th anniversary, it’s incredible to reflect on how far we’ve come as a business. We are the only resin manufacturer in Spain, and we have played a significant role in the evolution of agarose resins. Looking ahead, we plan to invest approximately $10 million over the next five years to expand our capabilities and strengthen our role as a partner of choice for companies developing biologics and advanced therapies.”